Kazia Therapeutics (KZIA) Net Income towards Common Stockholders (2009 - 2024)

Kazia Therapeutics (KZIA) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$8.0 million in Q2 2017.

• Quarterly Net Income towards Common Stockholders rose 11.01% year-over-year to -$8.0 million in Q2 2017, while the trailing twelve-month figure through Dec 2018 was -$8.0 million (up 69.25% YoY) and the FY2025 annual result came in at -$13.3 million, up 24.87% from the prior year.
• Net Income towards Common Stockholders improved to -$8.0 million in Q2 2017, from -$9.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.1 million in Q4 2015 to a low of -$3055.3 billion in Q4 2013.
• A 5-year average of -$509.2 billion and a median of -$8.5 million in 2016 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2014 — Net Income towards Common Stockholders surged 100.0% — and 2016, when it slumped 76.11%.
• Tracing KZIA's Net Income towards Common Stockholders over 5 years: stood at -$3055.3 billion in 2013, then surged by 100.0% to -$6.4 million in 2014, then gained by 19.57% to -$5.1 million in 2015, then tumbled by 76.11% to -$9.0 million in 2016, then gained by 11.42% to -$8.0 million in 2017.
• The last three Net Income towards Common Stockholders figures came in at -$8.0 million (Q2 2017), -$9.0 million (Q4 2016), and -$9.0 million (Q2 2016), per Business Quant data.